Copyright
©The Author(s) 2018.
World J Hepatol. Oct 27, 2018; 10(10): 662-669
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.662
Published online Oct 27, 2018. doi: 10.4254/wjh.v10.i10.662
Study | Complement component | Alcoholic liver disease | Species |
Järveläinen et al[10] | C1, Crry, CD59 | Alcohol-induced injury | Rat |
Bykov et al[11] | C3 | Liver steatosis | Mouse |
Pritchard et al[8] | C3, C5, DAF | Fatty liver | Mouse |
He et al[7] | C3 | Liver steatosis | Mouse |
Cohen et al[13] | C1q | Alcohol-induced injury | Mouse |
Wlazlo et al[27] | C3 | Liver steatosis | Human |
Shen et al[6] | C3 | Alcoholic hepatitis | Mouse |
Maslowska et al[30] | Factor D | Alcoholic hepatitis | Mouse |
Type of regulators | Regulators | Functions |
Complement regulatory protein | DAF/CD55, Crry, FH, FI | Inhibit C3, C5 convertase |
CD59, protein S, clusterin | Inhibit MAC | |
Complement inhibitor | C1-INH | Inhibit C1r, C1s |
Targeted inhibitor | h5G1, 1-ScFv | Inhibit C5 activation |
RNA aptamer | Specifically bind C1q, C5 |
- Citation: Lin CJ, Hu ZG, Yuan GD, Lei B, He SQ. Complements are involved in alcoholic fatty liver disease, hepatitis and fibrosis. World J Hepatol 2018; 10(10): 662-669
- URL: https://www.wjgnet.com/1948-5182/full/v10/i10/662.htm
- DOI: https://dx.doi.org/10.4254/wjh.v10.i10.662